Funding for this research was provided by:
Eli Lilly and Company (N/A)
Received: 9 August 2020
Accepted: 27 November 2020
First Online: 5 January 2021
Ethics approval and consent to participate
: This study was approved by the Partners HealthCare institutional review board, and the requirement for informed consent was waived.
: Not applicable (the manuscript does not contain any individual person’s data in any form).
: Alexander Turchin declares research funding from Astra Zeneca, Edwards, Eli Lilly and Company, Novo Nordisk, Pfizer and Sanofi; consulting fees from Proteomics International; and equity in Brio Systems. Jianmin Wu, Zhenxiang Zhao, Ginger Haynes, Xuanyao He and Ayad Ali are employees and stockholders of Eli Lilly and Company. Xiaomei Peng is a former employee of Eli Lilly and Company.The rest of the authors have no potential conflicts of interest to disclose, including relevant financial interests, activities, relationships, and affiliations with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.